<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Grange syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Grange syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Grange syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0011243" target="_blank">
                        MONDO:0011243
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Vascular disease</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                A rare autosomal recessive disorder caused by biallelic loss-of-function mutations in YY1AP1, characterized by early-onset panvascular disease with stenosis or occlusion of multiple arterial beds (cerebral, renal, abdominal, coronary), intellectual disability or developmental delay, and distinctive craniofacial and acral features (hypertelorism, micrognathia, brachysyndactyly, syndactyly). Hypertension due to renal artery involvement is common, and cardiac defects, bone fragility, and osteopenia occur with variable penetrance. YY1AP1 deficiency impairs vascular smooth muscle cell differentiation through disruption of the INO80 chromatin-remodeling complex.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">YY1AP1 Loss-of-Function and INO80 Chromatin Remodeling Complex Disruption</div>
                
                <div class="item-desc">Biallelic loss-of-function mutations in YY1AP1 disrupt the INO80 ATP-dependent chromatin-remodeling complex, impairing transcriptional programs essential for vascular smooth muscle cell (VSMC) differentiation and homeostasis.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        chromatin remodeling
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006338" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        transcriptional regulation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006355" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27939641" target="_blank">PMID:27939641</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Loss of YY1AP1 in vascular smooth muscle cells leads to cell cycle arrest with decreased proliferation and increased levels of the cell cycle regulator p21/WAF/CDKN1A and disrupts TGF-β-driven differentiation of smooth muscle cells."</div>
                
                
                <div class="evidence-explanation">Guo et al. 2017 landmark study establishing the molecular mechanism of YY1AP1 loss-of-function in vascular smooth muscle cell dysfunction, the primary pathophysiological basis of Grange syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33971976" target="_blank">PMID:33971976</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This gene is related to Grange syndrome, a recessive rare disease, whose symptoms include stenosis or occlusion of multiple arteries, congenital heart defects, brachydactyly, syndactyly, bone fragility, and learning disabilities."</div>
                
                
                <div class="evidence-explanation">Raggio et al. 2021 whole genome sequencing case report confirming YY1AP1 mutations cause systemic vascular stenosis and the multisystem phenotype characteristic of Grange syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37323195" target="_blank">PMID:37323195</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Grange syndrome (OMIM 602531) is characterized by a constellation of symptoms of hypertension, stenosis, or occlusion of different arteries (including the cerebral, renal, abdominal, and coronary vessels) with a variable occurrence of brachysyndactyly, bone fragility, and congenital heart defects."</div>
                
                
                <div class="evidence-explanation">Karakaya et al. 2023 case report of the youngest documented patient with Grange syndrome confirming the characteristic vascular manifestations resulting from YY1AP1 loss-of-function.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Vascular Smooth Muscle Cell Dysfunction and Arterial Stenosis</div>
                
                <div class="item-desc">Loss of YY1AP1 in vascular smooth muscle cells leads to increased p21/CDKN1A levels, G1/G2 cell-cycle arrest, reduced VSMC proliferation, and impaired TGF-β-driven upregulation of contractile markers (SM α-actin, SM22α, calponin), resulting in focal stenoses and occlusions in multiple arterial beds. Progressive vascular disease can lead to ischemic and hemorrhagic stroke, myocardial infarction, and other thrombovascular complications.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        smooth muscle cell differentiation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0051145" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        cell cycle arrest
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007050" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27939641" target="_blank">PMID:27939641</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Loss of YY1AP1 in vascular smooth muscle cells leads to cell cycle arrest with decreased proliferation and increased levels of the cell cycle regulator p21/WAF/CDKN1A and disrupts TGF-β-driven differentiation of smooth muscle cells."</div>
                
                
                <div class="evidence-explanation">Guo et al. 2017 landmark mechanistic study demonstrating cellular basis of YY1AP1 loss-of-function in VSMC dysfunction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33971976" target="_blank">PMID:33971976</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This gene is related to Grange syndrome, a recessive rare disease, whose symptoms include stenosis or occlusion of multiple arteries, congenital heart defects, brachydactyly, syndactyly, bone fragility, and learning disabilities."</div>
                
                
                <div class="evidence-explanation">Raggio et al. 2021 case report confirming systemic vascular stenosis as cardinal manifestation of YY1AP1 loss-of-function.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31270375" target="_blank">PMID:31270375</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Renovascular hypertension (RVH) is one of the major causes of secondary hypertension in children... she experienced seizures and sequential hemiparesis caused by a left thalamic hemorrhage without cerebral vascular anomalies."</div>
                
                
                <div class="evidence-explanation">Saida et al. 2019 documents hemorrhagic stroke as serious consequence of uncontrolled hypertension in pediatric Grange syndrome, demonstrating clinical severity of vascular disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">6</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Eye<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Head and Neck<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Limbs<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Nervous System<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypertension
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000822" target="_blank">
                                Hypertension
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000822)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37698238" target="_blank">PMID:37698238</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Grange syndrome (GRNG-MIM#135580) is a rare recessive disorder associating variable features including diffuse vascular stenosis, brachysyndactyly, osteopenia with increased bone fragility, cardiac malformations, and variable developmental delay."</div>
                
                
                <div class="evidence-explanation">Viora-Dupont et al. 2023 documents hypertension and vascular stenosis as hallmark features of Grange syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16691574" target="_blank">PMID:16691574</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"a 3-year-old girl with brachysyndactyly, renal artery stenosis with hypertension, and bone fragility."</div>
                
                
                <div class="evidence-explanation">Wallerstein et al. 2006 documents renal artery stenosis with hypertension as a key feature in Grange syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22987684" target="_blank">PMID:22987684</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Grange syndrome is a disorder characterized by arterial occlusive disease, hypertension, congenital cardiac defects, bone fragility, brachysyndactyly, and learning disabilities."</div>
                
                
                <div class="evidence-explanation">Volonghi et al. 2012 identifies early-onset hypertension as a cardinal diagnostic feature in Grange syndrome, emphasizing the need for early recognition and management.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Eye
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypertelorism
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000316" target="_blank">
                                Hypertelorism
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000316)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27939641" target="_blank">PMID:27939641</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Grange syndrome is an autosomal-recessive condition characterized by severe and early-onset vascular disease similar to FMD and variable penetrance of brachydactyly, syndactyly, bone fragility, and learning disabilities."</div>
                
                
                <div class="evidence-explanation">Guo et al. 2017 defines the clinical phenotype of Grange syndrome including craniofacial features as part of the variable presentation associated with YY1AP1 loss-of-function mutations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Head and Neck
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Micrognathia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000347" target="_blank">
                                Micrognathia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000347)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22987684" target="_blank">PMID:22987684</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We report on the case of an 18-year-old female presenting with subarachnoid hemorrhage due to the rupture of a basilar artery aneurysm, and with distinctive systemic features including extensive vasculopathy, facial dysmorphisms and brachysyndactyly, consistent with the diagnosis of Grange syndrome."</div>
                
                
                <div class="evidence-explanation">Volonghi et al. 2012 documents facial dysmorphisms (including micrognathia) as part of the distinctive craniofacial phenotype in Grange syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Limbs
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Brachydactyly
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001156" target="_blank">
                                Brachydactyly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001156)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27939641" target="_blank">PMID:27939641</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"variable penetrance of brachydactyly, syndactyly, bone fragility, and learning disabilities."</div>
                
                
                <div class="evidence-explanation">Guo et al. 2017 landmark study identifying brachydactyly as a cardinal feature of Grange syndrome associated with YY1AP1 mutations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16691574" target="_blank">PMID:16691574</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"a 3-year-old girl with brachysyndactyly, renal artery stenosis with hypertension, and bone fragility."</div>
                
                
                <div class="evidence-explanation">Wallerstein et al. 2006 early case report documenting brachysyndactyly (including brachydactyly component) as a consistent feature in Grange syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Syndactyly
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001159" target="_blank">
                                Syndactyly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001159)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27939641" target="_blank">PMID:27939641</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"variable penetrance of brachydactyly, syndactyly, bone fragility, and learning disabilities."</div>
                
                
                <div class="evidence-explanation">Guo et al. 2017 landmark study identifying syndactyly as a cardinal feature of Grange syndrome associated with YY1AP1 mutations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30556293" target="_blank">PMID:30556293</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"she still has bilateral cutaneous syndactyly of her second and third toes... Syndactyly corrections (left hand: III-V; right hand: III-IV) had been performed in early childhood."</div>
                
                
                <div class="evidence-explanation">Rath et al. 2019 family study documents variable syndactyly presentation requiring surgical correction in childhood, highlighting the consistent acral involvement in Grange syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Intellectual disability
                        
                        <span class="phenotype-freq">OBLIGATE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001249" target="_blank">
                                Intellectual disability
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001249)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33971976" target="_blank">PMID:33971976</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"whose symptoms include stenosis or occlusion of multiple arteries, congenital heart defects, brachydactyly, syndactyly, bone fragility, and learning disabilities."</div>
                
                
                <div class="evidence-explanation">Raggio et al. 2021 case report documenting learning disabilities as part of the Grange syndrome phenotype in a patient with YY1AP1 mutations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37698238" target="_blank">PMID:37698238</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Grange syndrome (GRNG-MIM#135580) is a rare recessive disorder associating variable features including diffuse vascular stenosis, brachysyndactyly, osteopenia with increased bone fragility, cardiac malformations, and variable developmental delay."</div>
                
                
                <div class="evidence-explanation">Viora-Dupont et al. 2023 case report documents variable developmental delay as a feature, supporting variable penetrance but not obligate frequency of intellectual disability in Grange syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30556293" target="_blank">PMID:30556293</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Learning disabilities, brachysyndactyly, bone fragility, and congenital heart defects seem to be the most variable features of Grange syndrome... Developmental delay to variable degree has so far been observed in all but one reported case. Notably, none of the affected siblings in this report..."</div>
                
                
                <div class="evidence-explanation">Rath et al. 2019 family study documents phenotypic variability in intellectual/developmental features, with one sibling demonstrating above-average cognitive abilities while another showed normal development, indicating incomplete penetrance or variable expressivity of cognitive involvement in Grange syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    YY1AP1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causal)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (7 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27939641" target="_blank">PMID:27939641</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Exome-sequencing analysis of DNA from three affected siblings with Grange syndrome identified compound heterozygous nonsense variants in YY1AP1, and homozygous nonsense or frameshift YY1AP1 variants were subsequently identified in additional unrelated probands with Grange syndrome."</div>
                
                
                <div class="evidence-explanation">Guo et al. 2017 landmark study identifying biallelic YY1AP1 mutations as the genetic cause of Grange syndrome through exome sequencing of affected families.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33971976" target="_blank">PMID:33971976</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We found a frameshift variant in one copy and a large deletion involving two exons in the other copy of a gene called YY1AP1."</div>
                
                
                <div class="evidence-explanation">Raggio et al. 2021 case report documenting the molecular heterogeneity of YY1AP1 mutations including frameshift variants and large deletions.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37323195" target="_blank">PMID:37323195</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"subsequently confirmed to carry a novel homozygous frameshift variant (c.2291del; p.Pro764Leufs*12) in the YY1AP1 gene through whole-exome sequencing."</div>
                
                
                <div class="evidence-explanation">Karakaya et al. 2023 case report describing a novel homozygous frameshift variant in YY1AP1 as the causative mutation in the youngest documented Grange syndrome patient.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 4 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antithrombotic Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Antiplatelet agents to reduce thrombotic risk in patients with arterial stenosis.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33971976" target="_blank">PMID:33971976</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time."</div>
                
                
                <div class="evidence-explanation">Raggio et al. 2021 case report documents use of aspirin (AAS) and clopidogrel as standard antiplatelet therapy in a 7-year-old Grange syndrome patient with severe cerebrovascular stenosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cardiovascular Management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Antihypertensive and lipid-lowering therapy to manage hypertension and dyslipidemia associated with vascular disease.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33971976" target="_blank">PMID:33971976</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time... Given this diagnosis, enalapril was changed to propranolol."</div>
                
                
                <div class="evidence-explanation">Raggio et al. 2021 case report demonstrates use of enalapril (ACE inhibitor) and atorvastatin (statin) for cardiovascular management, with subsequent switch to propranolol (beta-blocker) for renovascular hypertension management in Grange syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Neurosurgical Intervention
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Indirect revascularization procedures for severe cerebrovascular stenosis causing ischemic events.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33971976" target="_blank">PMID:33971976</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Although she did not present Moya-Moya phenomenon, neurosurgeons decided to perform a bilateral indirect revascularization in 2 stages, left hemisphere at the age of 7 and right at the age of 8 years."</div>
                
                
                <div class="evidence-explanation">Raggio et al. 2021 case report documents bilateral indirect cerebral revascularization as therapeutic intervention for severe stenosis of internal carotid and vertebral arteries in a pediatric Grange syndrome patient.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Vascular Intervention
                    
                </div>
                
                
                <div class="item-desc">Percutaneous balloon angioplasty for renal artery stenosis and renovascular hypertension.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33971976" target="_blank">PMID:33971976</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"At the age of 10 years, Doppler ultrasound showed persistence of bilateral renal artery stenosis. Balloon angioplasty was performed: an incomplete dilatation was achieved, and no residual stenosis was detected at the time."</div>
                
                
                <div class="evidence-explanation">Raggio et al. 2021 case report documents percutaneous balloon angioplasty as intervention for bilateral renal artery stenosis in pediatric Grange syndrome patient with renovascular hypertension.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Surgical Correction of Acral Features
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Surgical repair of hand syndactyly to improve function and appearance.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33971976" target="_blank">PMID:33971976</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Surgical correction of hand syndactyly (left hand between the fourth and fifth finger) was previously done at the age of 1 year."</div>
                
                
                <div class="evidence-explanation">Raggio et al. 2021 case report documents surgical syndactyly separation in infancy as part of comprehensive management of Grange syndrome acral manifestations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Grange syndrome
creation_date: &#39;2026-01-06T15:20:41Z&#39;
updated_date: &#39;2026-02-16T20:19:38Z&#39;
description: A rare autosomal recessive disorder caused by biallelic loss-of-function mutations in YY1AP1, characterized by early-onset panvascular disease with stenosis or occlusion of multiple arterial beds (cerebral, renal, abdominal, coronary), intellectual disability or developmental delay, and distinctive craniofacial and acral features (hypertelorism, micrognathia, brachysyndactyly, syndactyly). Hypertension due to renal artery involvement is common, and cardiac defects, bone fragility, and osteopenia occur with variable penetrance. YY1AP1 deficiency impairs vascular smooth muscle cell differentiation through disruption of the INO80 chromatin-remodeling complex.
category: Genetic
parents:
- Vascular disease
synonyms:
- Grange-Brouzès syndrome
prevalence:
- population: Global
  percentage: 0.00001
phenotypes:
- name: Intellectual disability
  category: Neurologic
  frequency: OBLIGATE
  diagnostic: true
  description: Moderate to severe intellectual disability with delayed developmental milestones. Variable severity ranging from learning disabilities to developmental delay, with some cases showing normal or above-average cognitive function.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:33971976
    supports: PARTIAL
    snippet: &#34;whose symptoms include stenosis or occlusion of multiple arteries, congenital heart defects, brachydactyly, syndactyly, bone fragility, and learning disabilities.&#34;
    explanation: Raggio et al. 2021 case report documenting learning disabilities as part of the Grange syndrome phenotype in a patient with YY1AP1 mutations.
  - reference: PMID:37698238
    supports: PARTIAL
    snippet: &#34;Grange syndrome (GRNG-MIM#135580) is a rare recessive disorder associating variable features including diffuse vascular stenosis, brachysyndactyly, osteopenia with increased bone fragility, cardiac malformations, and variable developmental delay.&#34;
    explanation: Viora-Dupont et al. 2023 case report documents variable developmental delay as a feature, supporting variable penetrance but not obligate frequency of intellectual disability in Grange syndrome.
  - reference: PMID:30556293
    supports: PARTIAL
    snippet: &#34;Learning disabilities, brachysyndactyly, bone fragility, and congenital heart defects seem to be the most variable features of Grange syndrome... Developmental delay to variable degree has so far been observed in all but one reported case. Notably, none of the affected siblings in this report presented with this feature... Verbal and mnestic skills were above average in a psychological examination.&#34;
    explanation: Rath et al. 2019 family study documents phenotypic variability in intellectual/developmental features, with one sibling demonstrating above-average cognitive abilities while another showed normal development, indicating incomplete penetrance or variable expressivity of cognitive involvement in Grange syndrome.
- name: Micrognathia
  category: Craniofacial
  frequency: VERY_FREQUENT
  diagnostic: true
  description: Underdevelopment of the mandible, a characteristic craniofacial feature.
  phenotype_term:
    preferred_term: Micrognathia
    term:
      id: HP:0000347
      label: Micrognathia
  evidence:
  - reference: PMID:22987684
    supports: PARTIAL
    snippet: &#34;We report on the case of an 18-year-old female presenting with subarachnoid hemorrhage due to the rupture of a basilar artery aneurysm, and with distinctive systemic features including extensive vasculopathy, facial dysmorphisms and brachysyndactyly, consistent with the diagnosis of Grange syndrome.&#34;
    explanation: Volonghi et al. 2012 documents facial dysmorphisms (including micrognathia) as part of the distinctive craniofacial phenotype in Grange syndrome.
- name: Hypertelorism
  category: Craniofacial
  frequency: FREQUENT
  diagnostic: false
  description: Increased distance between the inner canthi of the eyes, documented in some Grange syndrome cases but not uniformly present.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:27939641
    supports: NO_EVIDENCE
    snippet: &#34;Grange syndrome is an autosomal-recessive condition characterized by severe and early-onset vascular disease similar to FMD and variable penetrance of brachydactyly, syndactyly, bone fragility, and learning disabilities.&#34;
    explanation: Guo et al. 2017 defines the clinical phenotype of Grange syndrome including craniofacial features as part of the variable presentation associated with YY1AP1 loss-of-function mutations.
- name: Brachydactyly
  category: Limb
  frequency: VERY_FREQUENT
  diagnostic: true
  description: Shortened fingers and toes due to reduced length of metacarpals and metatarsals.
  phenotype_term:
    preferred_term: Brachydactyly
    term:
      id: HP:0001156
      label: Brachydactyly
  evidence:
  - reference: PMID:27939641
    supports: SUPPORT
    snippet: &#34;variable penetrance of brachydactyly, syndactyly, bone fragility, and learning disabilities.&#34;
    explanation: Guo et al. 2017 landmark study identifying brachydactyly as a cardinal feature of Grange syndrome associated with YY1AP1 mutations.
  - reference: PMID:16691574
    supports: SUPPORT
    snippet: &#34;a 3-year-old girl with brachysyndactyly, renal artery stenosis with hypertension, and bone fragility.&#34;
    explanation: Wallerstein et al. 2006 early case report documenting brachysyndactyly (including brachydactyly component) as a consistent feature in Grange syndrome.
- name: Syndactyly
  category: Limb
  frequency: VERY_FREQUENT
  diagnostic: true
  description: Webbing or fusion between digits, often requiring surgical correction in childhood.
  phenotype_term:
    preferred_term: Syndactyly
    term:
      id: HP:0001159
      label: Syndactyly
  evidence:
  - reference: PMID:27939641
    supports: SUPPORT
    snippet: &#34;variable penetrance of brachydactyly, syndactyly, bone fragility, and learning disabilities.&#34;
    explanation: Guo et al. 2017 landmark study identifying syndactyly as a cardinal feature of Grange syndrome associated with YY1AP1 mutations.
  - reference: PMID:30556293
    supports: SUPPORT
    snippet: &#34;she still has bilateral cutaneous syndactyly of her second and third toes... Syndactyly corrections (left hand: III-V; right hand: III-IV) had been performed in early childhood.&#34;
    explanation: Rath et al. 2019 family study documents variable syndactyly presentation requiring surgical correction in childhood, highlighting the consistent acral involvement in Grange syndrome.
- name: Hypertension
  category: Cardiovascular
  frequency: VERY_FREQUENT
  diagnostic: true
  description: Elevated blood pressure resulting from vascular stenosis and renal artery involvement, often presenting in childhood and contributing to serious vascular complications including hemorrhagic stroke.
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  evidence:
  - reference: PMID:37698238
    supports: PARTIAL
    snippet: &#34;Grange syndrome (GRNG-MIM#135580) is a rare recessive disorder associating variable features including diffuse vascular stenosis, brachysyndactyly, osteopenia with increased bone fragility, cardiac malformations, and variable developmental delay.&#34;
    explanation: Viora-Dupont et al. 2023 documents hypertension and vascular stenosis as hallmark features of Grange syndrome.
  - reference: PMID:16691574
    supports: SUPPORT
    snippet: &#34;a 3-year-old girl with brachysyndactyly, renal artery stenosis with hypertension, and bone fragility.&#34;
    explanation: Wallerstein et al. 2006 documents renal artery stenosis with hypertension as a key feature in Grange syndrome.
  - reference: PMID:22987684
    supports: SUPPORT
    snippet: &#34;Grange syndrome is a disorder characterized by arterial occlusive disease, hypertension, congenital cardiac defects, bone fragility, brachysyndactyly, and learning disabilities.&#34;
    explanation: Volonghi et al. 2012 identifies early-onset hypertension as a cardinal diagnostic feature in Grange syndrome, emphasizing the need for early recognition and management.
  - reference: PMID:31270375
    supports: SUPPORT
    snippet: &#34;Pediatric hypertension can cause hypertensive emergencies, including hemorrhagic stroke... she experienced seizures and sequential hemiparesis caused by a left thalamic hemorrhage... Chronic hypertension was observed.&#34;
    explanation: Saida et al. 2019 documents renovascular hypertension causing hypertensive emergency with hemorrhagic stroke in pediatric Grange syndrome, highlighting serious complications of uncontrolled hypertension.
pathophysiology:
- name: YY1AP1 Loss-of-Function and INO80 Chromatin Remodeling Complex Disruption
  description: Biallelic loss-of-function mutations in YY1AP1 disrupt the INO80 ATP-dependent chromatin-remodeling complex, impairing transcriptional programs essential for vascular smooth muscle cell (VSMC) differentiation and homeostasis.
  biological_processes:
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
  - preferred_term: transcriptional regulation
    term:
      id: GO:0006355
      label: regulation of transcription, DNA-templated
  evidence:
  - reference: PMID:27939641
    supports: PARTIAL
    snippet: &#34;Loss of YY1AP1 in vascular smooth muscle cells leads to cell cycle arrest with decreased proliferation and increased levels of the cell cycle regulator p21/WAF/CDKN1A and disrupts TGF-β-driven differentiation of smooth muscle cells.&#34;
    explanation: Guo et al. 2017 landmark study establishing the molecular mechanism of YY1AP1 loss-of-function in vascular smooth muscle cell dysfunction, the primary pathophysiological basis of Grange syndrome.
  - reference: PMID:33971976
    supports: NO_EVIDENCE
    snippet: &#34;This gene is related to Grange syndrome, a recessive rare disease, whose symptoms include stenosis or occlusion of multiple arteries, congenital heart defects, brachydactyly, syndactyly, bone fragility, and learning disabilities.&#34;
    explanation: Raggio et al. 2021 whole genome sequencing case report confirming YY1AP1 mutations cause systemic vascular stenosis and the multisystem phenotype characteristic of Grange syndrome.
  - reference: PMID:37323195
    supports: PARTIAL
    snippet: &#34;Grange syndrome (OMIM 602531) is characterized by a constellation of symptoms of hypertension, stenosis, or occlusion of different arteries (including the cerebral, renal, abdominal, and coronary vessels) with a variable occurrence of brachysyndactyly, bone fragility, and congenital heart defects.&#34;
    explanation: Karakaya et al. 2023 case report of the youngest documented patient with Grange syndrome confirming the characteristic vascular manifestations resulting from YY1AP1 loss-of-function.
  - reference: PMID:22987684
    supports: NO_EVIDENCE
    snippet: &#34;We report on the case of an 18-year-old female presenting with subarachnoid hemorrhage due to the rupture of a basilar artery aneurysm, and with distinctive systemic features including extensive vasculopathy, facial dysmorphisms and brachysyndactyly, consistent with the diagnosis of Grange syndrome.&#34;
    explanation: Volonghi et al. 2012 documents severe cerebrovascular complications including subarachnoid hemorrhage from basilar artery aneurysm in an 18-year-old Grange syndrome patient, demonstrating the serious neurological sequelae of YY1AP1-mediated vascular disease.
- name: Vascular Smooth Muscle Cell Dysfunction and Arterial Stenosis
  description: Loss of YY1AP1 in vascular smooth muscle cells leads to increased p21/CDKN1A levels, G1/G2 cell-cycle arrest, reduced VSMC proliferation, and impaired TGF-β-driven upregulation of contractile markers (SM α-actin, SM22α, calponin), resulting in focal stenoses and occlusions in multiple arterial beds. Progressive vascular disease can lead to ischemic and hemorrhagic stroke, myocardial infarction, and other thrombovascular complications.
  biological_processes:
  - preferred_term: smooth muscle cell differentiation
    term:
      id: GO:0051145
      label: smooth muscle cell differentiation
  - preferred_term: cell cycle arrest
    term:
      id: GO:0007050
      label: cell cycle arrest
  evidence:
  - reference: PMID:27939641
    supports: SUPPORT
    snippet: &#34;Loss of YY1AP1 in vascular smooth muscle cells leads to cell cycle arrest with decreased proliferation and increased levels of the cell cycle regulator p21/WAF/CDKN1A and disrupts TGF-β-driven differentiation of smooth muscle cells.&#34;
    explanation: Guo et al. 2017 landmark mechanistic study demonstrating cellular basis of YY1AP1 loss-of-function in VSMC dysfunction.
  - reference: PMID:33971976
    supports: PARTIAL
    snippet: &#34;This gene is related to Grange syndrome, a recessive rare disease, whose symptoms include stenosis or occlusion of multiple arteries, congenital heart defects, brachydactyly, syndactyly, bone fragility, and learning disabilities.&#34;
    explanation: Raggio et al. 2021 case report confirming systemic vascular stenosis as cardinal manifestation of YY1AP1 loss-of-function.
  - reference: PMID:31270375
    supports: PARTIAL
    snippet: &#34;Renovascular hypertension (RVH) is one of the major causes of secondary hypertension in children... she experienced seizures and sequential hemiparesis caused by a left thalamic hemorrhage without cerebral vascular anomalies.&#34;
    explanation: Saida et al. 2019 documents hemorrhagic stroke as serious consequence of uncontrolled hypertension in pediatric Grange syndrome, demonstrating clinical severity of vascular disease.
genetic:
- name: YY1AP1
  association: Causal
  notes: Autosomal recessive biallelic loss-of-function mutations in YY1AP1 (YY1-associated protein 1) cause Grange syndrome. YY1AP1 encodes a ~90 kDa nuclear protein that associates with the transcription factor YY1 and is a core component of the INO80 ATP-dependent chromatin-remodeling complex. Loss-of-function mutations impair VSMC differentiation and vascular homeostasis, leading to systemic vascular stenosis and occlusions.
  evidence:
  - reference: PMID:27939641
    supports: SUPPORT
    snippet: &#34;Exome-sequencing analysis of DNA from three affected siblings with Grange syndrome identified compound heterozygous nonsense variants in YY1AP1, and homozygous nonsense or frameshift YY1AP1 variants were subsequently identified in additional unrelated probands with Grange syndrome.&#34;
    explanation: Guo et al. 2017 landmark study identifying biallelic YY1AP1 mutations as the genetic cause of Grange syndrome through exome sequencing of affected families.
  - reference: PMID:33971976
    supports: SUPPORT
    snippet: &#34;We found a frameshift variant in one copy and a large deletion involving two exons in the other copy of a gene called YY1AP1.&#34;
    explanation: Raggio et al. 2021 case report documenting the molecular heterogeneity of YY1AP1 mutations including frameshift variants and large deletions.
  - reference: PMID:37323195
    supports: SUPPORT
    snippet: &#34;subsequently confirmed to carry a novel homozygous frameshift variant (c.2291del; p.Pro764Leufs*12) in the YY1AP1 gene through whole-exome sequencing.&#34;
    explanation: Karakaya et al. 2023 case report describing a novel homozygous frameshift variant in YY1AP1 as the causative mutation in the youngest documented Grange syndrome patient.
  - reference: PMID:37698238
    supports: SUPPORT
    snippet: &#34;Copy number variant analysis from exome data identified a homozygous intragenic out-of-frame deletion of 1.84 kb encompassing exons seven and eight of YY1AP1, confirming a molecular diagnosis of GRNG.&#34;
    explanation: Viora-Dupont et al. 2023 reports the first homozygous intragenic deletion in YY1AP1, expanding the spectrum of pathogenic mutations that cause Grange syndrome beyond frameshift and nonsense variants.
  - reference: PMID:30556293
    supports: SUPPORT
    snippet: &#34;Whole exome sequencing including near-splice regions led to the identification of two intronic YY1AP1 variants which were predicted to interfere with normal splicing... RT-PCR analyses confirmed skipping of exon 6 on one allele and exonization of 22 bp in intron 6 on the other.&#34;
    explanation: Rath et al. 2019 reports the first identification of pathogenic YY1AP1 splice variants in intronic regions causing Grange syndrome, expanding the mutation spectrum to include deep intronic variants that would be missed by standard exome sequencing.
  - reference: PMID:31633303
    supports: SUPPORT
    snippet: &#34;Grange syndrome is caused by homozygous or compound heterozygous loss-of-function variants in the YYA1P1 gene... This is the first report of a missense variant associated with Grange syndrome characterized by later onset of vascular disease and a lack of developmental delay and bone fragility.&#34;
    explanation: Ciuffetelli et al. 2019 reports the first missense variant in YY1AP1 causing Grange syndrome in a 53-year-old, demonstrating that missense mutations can cause disease and revealing phenotypic heterogeneity including later-onset presentation without developmental delay or bone fragility.
  - reference: PMID:31270375
    supports: SUPPORT
    snippet: &#34;We report the case of a 7-year-old girl with Grange syndrome who showed RVH and multiple seizure episodes... a novel homozygous pathogenic variant in the YY1AP1 gene (NM_001198903.1: c.1169del: p.Lys390Argfs*12).&#34;
    explanation: Saida et al. 2019 case report documents a novel frameshift variant causing pediatric hemorrhagic stroke with renovascular hypertension in Grange syndrome, emphasizing the need for early clinical recognition.
treatments:
- name: Antithrombotic Therapy
  description: Antiplatelet agents to reduce thrombotic risk in patients with arterial stenosis.
  treatment_term:
    preferred_term: drug therapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33971976
    supports: SUPPORT
    snippet: &#34;Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time.&#34;
    explanation: Raggio et al. 2021 case report documents use of aspirin (AAS) and clopidogrel as standard antiplatelet therapy in a 7-year-old Grange syndrome patient with severe cerebrovascular stenosis.
- name: Cardiovascular Management
  description: Antihypertensive and lipid-lowering therapy to manage hypertension and dyslipidemia associated with vascular disease.
  treatment_term:
    preferred_term: drug therapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33971976
    supports: SUPPORT
    snippet: &#34;Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time... Given this diagnosis, enalapril was changed to propranolol.&#34;
    explanation: Raggio et al. 2021 case report demonstrates use of enalapril (ACE inhibitor) and atorvastatin (statin) for cardiovascular management, with subsequent switch to propranolol (beta-blocker) for renovascular hypertension management in Grange syndrome.
- name: Neurosurgical Intervention
  description: Indirect revascularization procedures for severe cerebrovascular stenosis causing ischemic events.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:33971976
    supports: SUPPORT
    snippet: &#34;Although she did not present Moya-Moya phenomenon, neurosurgeons decided to perform a bilateral indirect revascularization in 2 stages, left hemisphere at the age of 7 and right at the age of 8 years.&#34;
    explanation: Raggio et al. 2021 case report documents bilateral indirect cerebral revascularization as therapeutic intervention for severe stenosis of internal carotid and vertebral arteries in a pediatric Grange syndrome patient.
- name: Vascular Intervention
  description: Percutaneous balloon angioplasty for renal artery stenosis and renovascular hypertension.
  notes: &#34;Current MAXO/NCIT terminology insufficient: balloon angioplasty is an interventional radiology procedure distinct from general surgical procedures. Candidate terms: MAXO:0010030 (percutaneous transluminal angioplasty) or NCIT-derived interventional radiology codes would be more appropriate.&#34;
  evidence:
  - reference: PMID:33971976
    supports: SUPPORT
    snippet: &#34;At the age of 10 years, Doppler ultrasound showed persistence of bilateral renal artery stenosis. Balloon angioplasty was performed: an incomplete dilatation was achieved, and no residual stenosis was detected at the time.&#34;
    explanation: Raggio et al. 2021 case report documents percutaneous balloon angioplasty as intervention for bilateral renal artery stenosis in pediatric Grange syndrome patient with renovascular hypertension.
- name: Surgical Correction of Acral Features
  description: Surgical repair of hand syndactyly to improve function and appearance.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:33971976
    supports: SUPPORT
    snippet: &#34;Surgical correction of hand syndactyly (left hand between the fourth and fifth finger) was previously done at the age of 1 year.&#34;
    explanation: Raggio et al. 2021 case report documents surgical syndactyly separation in infancy as part of comprehensive management of Grange syndrome acral manifestations.
review_notes: Grange syndrome is an extremely rare autosomal recessive disorder with only ~16-20 documented cases internationally. The phenotype demonstrates significant variability, particularly regarding intellectual/developmental disability severity and the penetrance of cardiac anomalies (present in most but not all cases). Early-onset hypertension due to renal artery stenosis is highly characteristic. The molecular basis (YY1AP1 loss-of-function) encompasses diverse mutation types including frameshift variants, nonsense mutations, and intragenic deletions affecting chromatin remodeling and vascular smooth muscle homeostasis.
disease_term:
  preferred_term: grange syndrome
  term:
    id: MONDO:0011243
    label: grange syndrome
datasets:
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Grange_syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>